Arbor receives $35 million in financing
ATLANTA Drug maker Arbor Pharmaceuticals has obtained nearly $35 million in financing, the company said Thursday.
Arbor said the $34.8 million included a $17.5 million investment in the form of Series B Preferred Stock, mostly from Signet Healthcare Partners, while the rest was in the form of a loan provided by investors, as well as portions of the loan and investment from existing shareholders. The company markets drugs for such indications as nasal hygiene and dermatitis.
“We are pleased with the commitment to Arbor demonstrated by our Series B investors,” Arbor president and CEO Ed Schutter said. “We have already completed several product license or acquisition agreements in the six months since the acquisition of Arbor by our original investment team and expect to use this funding to acquire other products.”
Axium, Firma Medical enter ED collaboration
LAKE MARY, Fla. A specialty pharmacy provider and a manufacturer will collaborate to provide treatments for erectile dysfunction.
Axium Healthcare Pharmacy and Firma Medical announced the partnership Wednesday where by Axium’s erectile dysfunction line of injectable compounded pharmaceuticals will be marketed to Firma’s physician and patient customers around the country. The companies said the deal would give Axium broader distribution while increasing the number of treatment options for Firma’s customers.
“Axium is pleased to partner with Firma Medical,” Axium EVP Greg Vaughn said. “This partnership shows our commitment in expanding our product offerings for patients with ED.”
Teva Women’s Health discusses emergency contraceptive at symposium
NEW YORK Nearly 1 million acts of unprotected sex take place in the United States every night. This statistic was a major talking point at a breakfast symposium for journalists on Thursday sponsored by Teva Women’s Health, manufacturer of the Plan B One-Step emergency contraceptive pill.
Those unprotected sex acts help contribute to the more than 3 million unintended pregnancies that affect U.S. women every year.
“Overall, it has been estimated that the widespread use of emergency contraception in the United States could prevent 1.7 million unintended pregnancies each year,” Columbia University Medical Center professor Anne Davis said in a statement on behalf of Teva.
Plan B One-Step (levonorgestrel) is a single pill available from behind the counter for girls and women ages 17 years and older, designed to be taken 72 hours after unprotected sex or contraceptive failure. But the four panelists at the symposium agreed that part of the challenge to increasing usage of the pill in the event of an “oops moment” is making people aware of it and combatting misinformation around it.
Visibility and convenience can go a long way to promoting usage, panelist and University of Southern California pharmacy professor Kathleen Besinque said, mentioning what she called “the condom look” — the anxious look on young men’s faces that is a telltale sign they’re looking for condoms. Similarly, customers looking for emergency contraception may be embarrassed to talk about it openly and thus afraid to ask where the pills are or worried the store doesn’t carry them.
“I talk to pharmacists all the time, and I try to encourage them to put the product where it can be seen,” Besinque told Drug Store News, adding that one way of ensuring visibility could include shelf tags near the shelf where condoms are kept.